安进Amgen Inc. (AMGN) 2014年年度报告「NASDAQ」.pdf

1、Dear Shareholders,2014 was an extraordinary year for Amgenfinancially,scientifically and organizationally.We moved markedly forward in growing our compelling portfolio of innovative and biosimilar medicines,and in transforming our company to deliver long-term,industry-leading innovation and financia

2、l returns.Delivering for ShareholdersIn 2014,we grew revenues at Amgen by 7 percent,surpassing$20 billion for the first time.Consistent with our international expansion objectives,we grew sales outside of the U.S.by double digits.We grew adjusted operating income*by 22 percent,reflecting our commitm

3、ent to expense discipline across the company.In addition,we grew free cash flow*40 percent to$7.8 billion.This strong financial performance,and our confidence in the longer-term outlook,enabled us to increase our dividend by 30 percent in 2014 and increase our share repurchase authorization to$4 bil

4、lion in total.We are on the path to meeting our commitment to return approximately 60 percent of adjusted net income*to shareholders annually through 2018,on average.Beginning a New Product Launch Cycle We delivered an extraordinary flow of data from our late-stage pipeline in 2014 and entered an ex

5、citing new product launch cycle.We advanced eight innovative,late-stage molecules in five therapeutic areas,all addressing serious illness and high unmet medical need.Six late-stage molecules generated positive,registration-enabling data in 2014,and four were filed with regulators.In December 2014,w

6、e received approval from the U.S.Food and Drug Administration(FDA)and began marketing our bispecific T-cell engager(BiTE)immunotherapy BLINCYTO(blinatumomab)for a type of acute lymphoblastic leukemia less than three months after submission.BLINCYTO is an important new treatment option for patients a